Markham
Markham
Markham, Ontario, Canada76 results · Page 1 of 4
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib | Bacterial Infections and Mycoses, Infections, Skin and Connective Tissue Diseases, Suppuration, bacterial infectious disease, hidradenitis, hidradenitis suppurativa, skin disease caused by bacterial infection, skin disorder, skin disorder caused by infection, sweat gland disorder | Recruiting | Phase 3 | 2026-10-09 | NCT06855498 | |
| Study of Patients Receiving DUPIXENT® for Atopic Dermatitis (AD) | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hypersensitivity, Immediate, Skin Diseases, Eczematous, Skin and Connective Tissue Diseases, atopic eczema, dermatitis, hereditary disease, hereditary skin disorder, immune system disorder, skin disorder | Active, not recruiting | Not stated | 2026-10-09 | NCT03428646 | |
| A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304) | Disorders of Excessive Somnolence, Dyssomnias, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Sleep Disorders, Intrinsic, Sleepiness, narcolepsy-cataplexy syndrome, nervous system disorder, psychiatric disorder, sleep-wake disorder | Recruiting | Phase 3 | 2026-10-07 | NCT07540897 | |
| A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2 | Disorders of Excessive Somnolence, Dyssomnias, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Sleep Disorders, Intrinsic, narcolepsy without cataplexy, nervous system disorder, psychiatric disorder, sleep-wake disorder | Recruiting | Phase 3 | 2026-10-07 | NCT07502443 | |
| A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1 | Cataplexy, Disorders of Excessive Somnolence, Dyssomnias, Fatigue, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Sleep Disorders, Intrinsic, narcolepsy, narcolepsy-cataplexy syndrome, nervous system disorder, psychiatric disorder, sleep-wake disorder | Recruiting | Phase 3 | 2026-10-07 | NCT07455383 | |
| Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria | Chronic Disease, Chronic Spontaneous Urticaria, Disease Attributes, Hypersensitivity, Immediate, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, chronic urticaria, immune system disorder, skin disorder, skin vascular disease, urticaria | Enrolling by invitation | Phase 3 | 2026-10-07 | NCT07256392 | |
| A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hypersensitivity, Immediate, Skin Diseases, Eczematous, Skin and Connective Tissue Diseases, atopic eczema, dermatitis, hereditary disease, hereditary skin disorder, immune system disorder, skin disorder | Recruiting | Phase 2 | 2026-10-06 | NCT07223697 | |
| A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hypersensitivity, Immediate, Skin Diseases, Eczematous, Skin and Connective Tissue Diseases, atopic eczema, dermatitis, hereditary disease, hereditary skin disorder, immune system disorder, skin disorder | Active, not recruiting | Phase 2 | 2026-10-06 | NCT07217015 | |
| A Study Evaluating APG777 in Atopic Dermatitis | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hypersensitivity, Immediate, Skin Diseases, Eczematous, Skin and Connective Tissue Diseases, atopic eczema, dermatitis, hereditary disease, hereditary skin disorder, immune system disorder, skin disorder | Active, not recruiting | Phase 2 | 2026-10-06 | NCT06395948 | |
| Platform of Randomized Adaptive Clinical Trials in Critical Illness | Respiration Disorders, respiratory failure, respiratory system disorder | Recruiting | Not applicable | 2026-10-06 | NCT05440851 | |
| Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012) | Bacterial Infections and Mycoses, Infections, Skin and Connective Tissue Diseases, Suppuration, bacterial infectious disease, hidradenitis, hidradenitis suppurativa, skin disease caused by bacterial infection, skin disorder, skin disorder caused by infection, sweat gland disorder | Active, not recruiting | Phase 2 | 2026-10-02 | NCT06956235 | |
| Study to Assess Change in Quality of Life of Risankizumab Treatment in Adult Participants With Moderate-to-Severe Plaque Psoriasis | Plaque Psoriasis | Recruiting | Not stated | 2026-10-01 | NCT07039110 | |
| A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis | Skin Diseases, Papulosquamous, Skin and Connective Tissue Diseases, palmoplantar pustulosis, psoriasis, skin disorder | Recruiting | Phase 2 | 2026-10-01 | NCT07013201 | |
| AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia | Community-Acquired Infections, Community-Acquired Pneumonia, Infections, lung disorder, pneumonia, respiratory system disorder, respiratory tract infectious disorder | Recruiting | Phase 3 | 2026-09-30 | NCT05848713 | |
| Canadian Real World Evidence Study of Brodalumab in Plaque Psoriasis to Understand the Impact on Quality of Life and Work Productivity | Skin Diseases, Papulosquamous, Skin and Connective Tissue Diseases, psoriasis, skin disorder | Active, not recruiting | Not stated | 2026-09-30 | NCT05132231 | |
| ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hypersensitivity, Immediate, Skin Diseases, Eczematous, Skin and Connective Tissue Diseases, atopic eczema, dermatitis, hereditary disease, hereditary skin disorder, immune system disorder, skin disorder | Active, not recruiting | Phase 2 | 2026-09-29 | NCT07011706 | |
| A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF | cardiovascular disorder, heart disorder, heart failure | Recruiting | Phase 3 | 2026-09-28 | NCT07761117 | |
| A Phase 2 Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Patients With Papulopustular Rosacea (PPR) | Papulopustular Rosacea, Skin and Connective Tissue Diseases, primary hyperoxaluria type 2, rosacea, skin disorder | Recruiting | Phase 2 | 2026-09-28 | NCT07681271 | |
| Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hypersensitivity, Immediate, Skin Diseases, Eczematous, Skin and Connective Tissue Diseases, atopic eczema, dermatitis, hereditary disease, hereditary skin disorder, immune system disorder, skin disorder | Recruiting | Phase 2 | 2026-09-28 | NCT06947993 | |
| Modifying PEST for Psoriatic Arthritis Screening | Skin Diseases, Papulosquamous, Skin and Connective Tissue Diseases, Spondylarthritis, Spondylarthropathies, arthritic joint disease, arthropathy, bone disorder, musculoskeletal system disorder, psoriasis, psoriatic arthritis, skin disorder, spondylitis, vertebral column disorder | Recruiting | Not applicable | 2026-09-28 | NCT06382051 | |
| A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2) | Plaque Psoriasis | Active, not recruiting | Phase 3 | 2026-09-28 | NCT06220604 | |
| A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo | Skin and Connective Tissue Diseases, hypopigmentation of the skin, skin disorder, skin pigmentation disorder, vitiligo | Active, not recruiting | Phase 3 | 2026-09-28 | NCT06163326 | |
| A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis | Plaque Psoriasis | Active, not recruiting | Phase 3 | 2026-09-25 | NCT06934226 | |
| A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet) | Plaque Psoriasis | Active, not recruiting | Phase 3 | 2026-09-25 | NCT06095102 | |
| A Study of Guselkumab and Interleukin-17 (IL-17) Inhibitor Therapies in Participants With Psoriatic Arthritis in Routine Clinical Practice | Skin Diseases, Papulosquamous, Skin and Connective Tissue Diseases, Spondylarthritis, Spondylarthropathies, arthritic joint disease, arthropathy, bone disorder, musculoskeletal system disorder, psoriasis, psoriatic arthritis, skin disorder, spondylitis, vertebral column disorder | Active, not recruiting | Not stated | 2026-09-25 | NCT05049798 |